Advertisement
Screener

AMARIN CORP PLC\UK (AMRN) SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense

2.1 / 5 stars · 35/82 Roast Me

AMARIN CORP PLC\UK SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense

AMARIN CORP PLC\UK (AMRN) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense of $426.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Notes › Valuation and Qualifying Accounts

us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense · last filed 2026-07-29

  • AMARIN CORP PLC\UK sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2026-06-30 was $209.11M, a 22.08% increase year-over-year.
  • AMARIN CORP PLC\UK sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2026-03-31 was $217.21M, a 16.77% increase year-over-year.
  • AMARIN CORP PLC\UK sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2025-12-31 was $220.49M, a 19.20% increase year-over-year.
  • AMARIN CORP PLC\UK sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2025-09-30 was $214.23M, a 8.14% increase year-over-year.
  • AMARIN CORP PLC\UK sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2025 was $792.02M, a 6.43% decline from fiscal 2024.
  • AMARIN CORP PLC\UK sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2024 was $846.45M, a 1.29% increase from fiscal 2023.
  • AMARIN CORP PLC\UK sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2023 was $835.68M, a 4.19% increase from fiscal 2022.
  • AMARIN CORP PLC\UK sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2022 was $802.12M, a 5.90% decline from fiscal 2021.
Period endSEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 3 monthSEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 3 month as first filedSEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 6 monthSEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 9 monthSEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 12 month
2026-06-30$209.11M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
$426.32M
10-Q · filed 2026-07-29
$646.81M
derived: sum of 3 quarters · filed 2026-07-29
$861.04M
derived: sum of 4 quarters · filed 2026-07-29
2026-03-31$217.21M
10-Q · filed 2026-04-29
$437.69M
derived: sum of 2 quarters · filed 2026-04-29
$651.92M
derived: sum of 3 quarters · filed 2026-04-29
$823.22M
derived: sum of 4 quarters · filed 2026-07-29
2025-12-31$220.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$434.71M
derived: sum of 2 quarters · filed 2026-03-02
$606.01M
derived: sum of 3 quarters · filed 2026-07-29
$792.02M
10-K · filed 2026-03-02
2025-09-30$214.23M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29
$385.53M
derived: sum of 2 quarters · filed 2026-07-29
$571.53M
10-Q · filed 2025-10-29
$756.51M
derived: sum of 4 quarters · filed 2026-07-29
2025-06-30$171.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
$357.31M
10-Q · filed 2026-07-29
$542.28M
derived: sum of 3 quarters · filed 2026-07-29
$740.40M
derived: sum of 4 quarters · filed 2026-07-29
2025-03-31$186.01M
10-Q · filed 2026-04-29
$370.99M
derived: sum of 2 quarters · filed 2026-04-29
$569.10M
derived: sum of 3 quarters · filed 2026-04-29
$841.75M
derived: sum of 4 quarters · filed 2026-04-29
2024-12-31$184.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$383.09M
derived: sum of 2 quarters · filed 2026-03-02
$655.74M
derived: sum of 3 quarters · filed 2026-03-02
$846.45M
10-K · filed 2026-03-02
2024-09-30$198.11M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29
$470.76M
derived: sum of 2 quarters · filed 2025-10-29
$661.47M
10-Q · filed 2025-10-29
$883.45M
derived: sum of 4 quarters · filed 2026-03-02
2024-06-30$272.65M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30
$463.36M
10-Q · filed 2025-07-30
$685.34M
derived: sum of 3 quarters · filed 2026-03-02
$907.45M
derived: sum of 4 quarters · filed 2026-03-02
2024-03-31$190.71M
10-Q · filed 2025-05-07
$235.89M
10-Q · filed 2024-05-01
$412.69M
derived: sum of 2 quarters · filed 2026-03-02
$634.80M
derived: sum of 3 quarters · filed 2026-03-02
$835.68M
derived: sum of 4 quarters · filed 2026-03-02
2023-12-31$221.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$444.09M
derived: sum of 2 quarters · filed 2026-03-02
$644.97M
derived: sum of 3 quarters · filed 2026-03-02
$835.68M
10-K · filed 2026-03-02
2023-09-30$222.11M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30
$422.99M
derived: sum of 2 quarters · filed 2024-10-30
$613.70M
10-Q · filed 2024-10-30
$830.87M
derived: sum of 4 quarters · filed 2024-10-30
2023-06-30$200.88M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31
$391.59M
10-Q · filed 2024-07-31
$608.76M
derived: sum of 3 quarters · filed 2024-07-31
$795.46M
derived: sum of 4 quarters · filed 2024-07-31
2023-03-31$190.71M
10-Q · filed 2024-05-01
$407.88M
derived: sum of 2 quarters · filed 2024-05-01
$594.58M
derived: sum of 3 quarters · filed 2024-05-01
$813.05M
derived: sum of 4 quarters · filed 2024-05-01
2022-12-31$217.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$403.87M
derived: sum of 2 quarters · filed 2024-02-29
$622.34M
derived: sum of 3 quarters · filed 2024-02-29
$802.12M
10-K · filed 2024-02-29
2022-09-30$186.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01
$405.17M
derived: sum of 2 quarters · filed 2023-11-01
$584.95M
10-Q · filed 2023-11-01
$809.79M
derived: sum of 4 quarters · filed 2023-11-01
2022-06-30$218.47M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02
$398.25M
10-Q · filed 2023-08-02
$623.10M
derived: sum of 3 quarters · filed 2023-08-02
$840.90M
derived: sum of 4 quarters · filed 2023-08-02
2022-03-31$179.77M
10-Q · filed 2023-05-03
$404.62M
derived: sum of 2 quarters · filed 2023-05-03
$622.43M
derived: sum of 3 quarters · filed 2023-05-03
$840.87M
derived: sum of 4 quarters · filed 2023-05-03
2021-12-31$224.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$442.65M
derived: sum of 2 quarters · filed 2023-03-01
$661.10M
derived: sum of 3 quarters · filed 2023-03-01
$852.42M
10-K · filed 2023-03-01
2021-09-30$217.81M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27
$436.25M
derived: sum of 2 quarters · filed 2022-10-27
$627.57M
10-Q · filed 2022-10-27
$865.18M
derived: sum of 4 quarters · filed 2022-10-27
2021-06-30$218.44M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
$409.77M
10-Q · filed 2022-08-03
$647.37M
derived: sum of 3 quarters · filed 2022-08-03
$870.60M
derived: sum of 4 quarters · filed 2022-08-03
2021-03-31$191.32M
10-Q · filed 2022-05-04
$428.93M
derived: sum of 2 quarters · filed 2022-05-04
$652.15M
derived: sum of 3 quarters · filed 2022-05-04
$830.43M
derived: sum of 4 quarters · filed 2022-05-04
2020-12-31$237.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$460.83M
derived: sum of 2 quarters · filed 2022-03-01
$639.11M
derived: sum of 3 quarters · filed 2022-03-01
$822.81M
10-K · filed 2022-03-01
2020-09-30$223.22M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
$401.50M
derived: sum of 2 quarters · filed 2021-11-03
$585.21M
10-Q · filed 2021-11-03
$761.91M
derived: sum of 4 quarters · filed 2021-11-03
2020-06-30$178.28M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$361.98M
10-Q · filed 2021-08-05
$538.69M
derived: sum of 3 quarters · filed 2021-08-05
$685.80M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$183.70M
10-Q · filed 2021-04-29
$360.41M
derived: sum of 2 quarters · filed 2021-04-29
$507.52M
derived: sum of 3 quarters · filed 2021-04-29
$634.55M
derived: sum of 4 quarters · filed 2021-04-29
2019-12-31$176.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$323.81M
derived: sum of 2 quarters · filed 2021-02-25
$450.85M
derived: sum of 3 quarters · filed 2021-02-25
$545.84M
10-K · filed 2021-02-25
2019-09-30$147.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$274.14M
derived: sum of 2 quarters · filed 2020-11-05
$369.13M
10-Q · filed 2020-11-05
$452.24M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30$127.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04
$222.03M
10-Q · filed 2020-08-04
$305.13M
derived: sum of 3 quarters · filed 2020-08-04
$373.45M
derived: sum of 4 quarters · filed 2020-08-04
2019-03-31$95.00M
10-Q · filed 2020-04-30
$178.10M
derived: sum of 2 quarters · filed 2020-04-30
$246.42M
derived: sum of 3 quarters · filed 2020-04-30
$307.41M
derived: sum of 4 quarters · filed 2020-04-30
2018-12-31$83.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
$151.42M
derived: sum of 2 quarters · filed 2020-02-25
$212.41M
derived: sum of 3 quarters · filed 2020-02-25
$258.27M
10-K · filed 2020-02-25
2018-09-30$68.31M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05
$129.31M
derived: sum of 2 quarters · filed 2019-11-05
$175.17M
10-Q · filed 2019-11-05
$229.13M
derived: sum of 4 quarters · filed 2019-11-05
2018-06-30$60.99M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31
$106.85M
10-Q · filed 2019-07-31
$160.81M
derived: sum of 3 quarters · filed 2019-07-31
$208.59M
derived: sum of 4 quarters · filed 2019-07-31
2018-03-31$45.86M
10-Q · filed 2019-05-01
$99.82M
derived: sum of 2 quarters · filed 2019-05-01
$147.60M
derived: sum of 3 quarters · filed 2019-05-01
$193.97M
derived: sum of 4 quarters · filed 2019-05-01
2017-12-31$53.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27
$101.74M
derived: sum of 2 quarters · filed 2019-02-27
$148.10M
derived: sum of 3 quarters · filed 2019-02-27
$178.53M
10-K · filed 2019-02-27
2017-09-30$47.78M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01
$94.14M
derived: sum of 2 quarters · filed 2018-11-01
$124.57M
10-Q · filed 2018-11-01
$157.85M
derived: sum of 4 quarters · filed 2018-11-01
2017-06-30$46.36M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01
$76.79M
10-Q · filed 2018-08-01
$110.07M
derived: sum of 3 quarters · filed 2018-08-01
$136.53M
derived: sum of 4 quarters · filed 2018-08-01
2017-03-31$30.43M
10-Q · filed 2018-05-02
$63.71M
derived: sum of 2 quarters · filed 2018-05-02
$90.16M
derived: sum of 3 quarters · filed 2018-05-02
$116.72M
derived: sum of 4 quarters · filed 2018-05-02
2016-12-31$33.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$59.74M
derived: sum of 2 quarters · filed 2018-02-27
$86.29M
derived: sum of 3 quarters · filed 2018-02-27
$104.60M
10-K · filed 2018-02-27
2016-09-30$26.45M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01
$53.01M
derived: sum of 2 quarters · filed 2017-11-01
$71.32M
10-Q · filed 2017-11-01
$89.60M
derived: sum of 4 quarters · filed 2017-11-01
2016-06-30$26.55M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02
$44.86M
10-Q · filed 2017-08-02
$63.15M
derived: sum of 3 quarters · filed 2017-08-02
$79.13M
derived: sum of 4 quarters · filed 2017-08-02
2016-03-31$18.31M
10-Q · filed 2017-05-03
$36.59M
derived: sum of 2 quarters · filed 2017-05-03
$52.57M
derived: sum of 3 quarters · filed 2017-05-03
$64.79M
derived: sum of 4 quarters · filed 2017-05-03
2015-12-31$18.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
$34.26M
derived: sum of 2 quarters · filed 2017-03-01
$46.48M
derived: sum of 3 quarters · filed 2017-03-01
$56.23M
10-K · filed 2017-03-01
2015-09-30$15.98M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03
$28.20M
derived: sum of 2 quarters · filed 2016-11-03
$37.94M
10-Q · filed 2016-11-03
$52.44M
derived: sum of 4 quarters · filed 2016-11-03
2015-06-30$12.22M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
$21.97M
10-Q · filed 2016-08-04
$36.46M
derived: sum of 3 quarters · filed 2016-08-04
$43.71M
derived: sum of 4 quarters · filed 2016-08-04
2015-03-31$9.74M
10-Q · filed 2016-05-05
$24.24M
derived: sum of 2 quarters · filed 2016-05-05
$31.48M
derived: sum of 3 quarters · filed 2016-05-05
$37.91M
derived: sum of 4 quarters · filed 2016-05-05
2014-12-31$14.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25
$21.74M
derived: sum of 2 quarters · filed 2016-02-25
$28.16M
derived: sum of 3 quarters · filed 2016-02-25
$32.46M
10-K · filed 2016-02-25
2014-09-30$7.24M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06
$13.66M
derived: sum of 2 quarters · filed 2015-08-06
$17.96M
10-Q · filed 2014-11-06
$22.26M
derived: sum of 4 quarters · filed 2015-08-06
2014-06-30$6.42M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06
$10.72M
10-Q · filed 2015-08-06
$15.02M
derived: sum of 3 quarters · filed 2015-08-06
$18.54M
derived: sum of 4 quarters · filed 2015-08-06
2014-03-31$4.30M
10-Q · filed 2015-05-08
$8.60M
derived: sum of 2 quarters · filed 2015-05-08
$12.12M
derived: sum of 3 quarters · filed 2015-05-08
$13.71M
derived: sum of 4 quarters · filed 2015-05-08
2013-12-31$4.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03
$7.82M
derived: sum of 2 quarters · filed 2015-03-03
$9.41M
derived: sum of 3 quarters · filed 2015-03-03
$11.65M
10-K · filed 2015-03-03
2013-09-30$3.52M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06
$5.11M
derived: sum of 2 quarters · filed 2014-11-06
$7.35M
10-Q · filed 2014-11-06
2013-06-30$1.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
$3.83M
10-Q · filed 2014-08-07
2013-03-31$2.23M
10-Q · filed 2014-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
Pulmatrix, Inc. (PULM)United States$0.006B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
Ernexa Therapeutics Inc. (ERNA)United States$0.006B